Danish vaccine developer Evaxion has released long-term data for its lead personalized cancer vaccine, with the shot scoring ...
The Big Pharma’s window to take up exclusive rights to Taysha’s lead asset, dubbed TSHA-102, has officially closed, according ...
A year ago, Pfizer tied a subcutaneous injection of the highest dose of the anti-GDF-15 antibody ponsegromab once every four ...
The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and ...
Xoma Royalty and Lava Therapeutics are turning the temperature down, dropping both the cash per share offer and closing cash ...
A pair of antibody-based biotech deals emerged late this week, encompassing separate licensing pacts from China’s Hansoh ...
Visara is launching with $37 million from I-Mab and will be led by Emmett Cunningham Jr., M.D., Ph.D., an ophthalmologist and ...
The biotech provided an update after the stock market closed Thursday, telling investors that it had been unable to align ...
To unpack what the new policy means for drug developers, Fierce Biotech’s Darren Incorvaia sat down with Torrey Cope, a ...
T, this time inking a deal worth up to $1.64 billion biobucks with Chinese biotech Pregene Biopharma. | Gilead’s Kite Pharma ...
Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. | Just a few months after surfacing at Orca Bio following his early ...
Praxis Precision Medicines’ commitment to forging ahead with ulixacaltamide in essential tremor (ET) has paid off. | The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback